Second line chemotherapy with irinotecan (CPT-11) and mitomycin-C (MMC) in patients with advanced/metastatic colorectal (CC) and gastric cancer (GC): A phase II trial.

被引：0
|
作者：
Papamichael, D
Bamias, A
Ioannides, G
Syrigos, K
Demosthenous, C
Pavlidis, N
机构：
[1] Univ Athens, Sotiria Hosp, Dept Med 3, Athens, Greece
[2] Ioannina Univ Hosp, Ioannina, Greece
[3] BO Cyprus Oncol Ctr, Nicosia, Cyprus
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
250
引用
收藏
页码：57 / 57
页数：1
相关论文
共 50 条
  • [41] Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy
    Aravantinos, G
    Skarlos, DV
    Kosmidis, P
    Georgoulias, V
    Sgouros, I
    Bafaloukos, D
    Androulakis, N
    Florou, S
    Fountzilas, G
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1999, 32 (03) : 209 - 219
  • [42] Phase I/II trial of gemcitabine (Gem) plus irinotecan (CPT-11) for metastatic pancreatic cancer (MPC)
    Yamai, Takuo
    Ioka, Tatsuya
    Sueyoshi, Hironari
    Takada, Ryoji
    Fukutake, Nobuyasu
    Ashida, Reiko
    Katayama, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [43] A phase II study of Irinotecan (Irino®) in combination with cisplatin as second line chemotherapy in patients with metastatic or locally advanced gastric cancer
    Shen, W-C
    Yang, T-S
    Chen, P-T
    Chen, J-S
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A21 - A21
  • [44] A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer
    Kim, Jung Han
    Kim, Hyeong Su
    Choi, Dae Ro
    Jang, Geundoo
    Kwon, Jung Hye
    Kim, Ho Young
    Jung, Joo Young
    Kim, Hyo Jung
    Song, Hun Ho
    Shin, Yun Ho
    Jung, So Young
    Kim, Byung Chun
    Zang, Dae Young
    ONCOLOGY LETTERS, 2011, 2 (06) : 1253 - 1256
  • [45] Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer
    Katsube, Takao
    Ogawa, Kenji
    Ichikawa, Wataru
    Fujii, Masashi
    Tokunaga, Akira
    Takagi, Yuh
    Kochi, Misugu
    Hayashi, Kazuhiko
    Kubota, Tetsuro
    Aiba, Keisuke
    Arai, Kuniyoshi
    Terashima, Masanori
    Kitajima, Masaki
    ANTI-CANCER DRUGS, 2007, 18 (05) : 605 - 610
  • [46] Weekly cisplatin (CDDP) plus irinotecan (CPT-11) as first line in patients with advanced gastric cancer (AGC)
    Constenla, Manuel
    Fernandez, Isaura
    Palacios, Patricia
    Arroyo, Fco Ramon G.
    Lorenzo, Isabel
    Salgado, Laura
    Varela, Silvia
    Clemente, Pedro L.
    ANNALS OF ONCOLOGY, 2004, 15 : 234 - 234
  • [47] Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial
    Souglakos, J
    Pallis, A
    Kakolyris, S
    Mavroudis, D
    Androulakis, N
    Kouroussis, C
    Agelaki, S
    Xenidis, N
    Milaki, G
    Georgoulias, V
    ONCOLOGY, 2005, 69 (05) : 384 - 390
  • [48] Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer
    Tsunoda, A.
    Yasuda, N.
    Nakao, K.
    Narita, K.
    Yamazaki, K.
    Watanabe, M.
    Suzuki, N.
    Kusano, M.
    ONCOLOGY, 2007, 72 (1-2) : 58 - 63
  • [49] A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer
    Reina, JJ
    Aparicio, J
    Salvador, J
    Pica, JMP
    Rueda, A
    Lorenzo, A
    de la Puente, CG
    Borrega, P
    Moreno-Nogueira, JA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (04) : 339 - 345
  • [50] Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU):: A phase II study
    Antón, A
    Aranda, E
    Carrato, A
    Marcuello, E
    Massutti, B
    Cervantes, A
    Abad, A
    Sastre, J
    Fenández-Martos, C
    Gallén, M
    Díaz-Rubio, E
    Huarte, L
    Balcells, M
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (08): : 639 - 643
12345